Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia

被引：30

作者：

Marani, Carlo ^{[1
]}

Clavio, Marino ^{[1
]}

Grasso, Raffaella ^{[1
]}

Colombo, Nicoletta ^{[1
]}

Guolo, Fabio ^{[1
]}

Kunkl, Annalisa ^{[2
]}

Ballerini, Filippo ^{[1
]}

Giannoni, Livia ^{[1
]}

Ghiggi, Chiara ^{[1
]}

Fugazza, Giuseppina ^{[1
]}

Ravetti, Jean-Louis ^{[2
]}

Gobbi, Marco ^{[1
]}

Miglino, Maurizio ^{[1
]}

机构：

[1] IRCCS AOU S Martino IST, Dept Hematol & Oncol, Genoa, Italy

[2] IRCCS AOU S Martino IST, Dept Pathol, Genoa, Italy

来源：

LEUKEMIA RESEARCH | 2013年 / 37卷 / 12期

关键词：

Acute myeloid leukemia; Minimal residual disease; Flow-cytometry; Wilms' tumor gene; Prognosis; Early response assessment; PROGNOSTIC-SIGNIFICANCE; RISK STRATIFICATION; GENE-EXPRESSION; RT-PCR; DIAGNOSIS; PREDICTS; SURVIVAL; RELAPSE; TIME; AML;

D O I：

10.1016/j.leukres.2013.07.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fifty uniformly treated adult AML patients were analyzed with respect to pre-treatment and post-induction risk factors. Forty-two patients achieving complete hematological remission were assessed for minimal residual disease (MRD) by WT1 gene expression; 34 by flow-cytometry (flow-MRD). Patients who were flow-MRD negative had a better 3-year disease-free (DFS; 79.5% vs. 27.3%; p =.032) compared with patients who were still positive after induction. Interestingly, DFS of flow-MRD positive patients was not related to the amount of flow-detected clone population (>= or < 1%, p =.41) but to WT1 reduction (Delta WT1, 3-year DFS; 46.2% vs. 0% if Delta WT1 was >= or < of 1.5 log, p =.001). In AML, combining MRD results provided by WT1 quantification and flow-cytometry improves the reliability of MRD-based prognostic stratification. Similar analyses by further larger studies should be advocated. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：1606 / 1611

页数：6

共 50 条

[21] Comparison of the Performance of Multiparameter Flow-Cytometry and wt1-RNA Levels in Detecting Minimal Residual Disease and Predicting Relapse in Patients with Acute Myeloid Leukemia
Rossi, Giovanni
Minervini, Mariella
Carella, Angelo Michele
de Waure, Chiara
Melillo, Lorella
D'Arena, Giovanni Francesco
Cascavilla, Nicola
Zini, Gina
BLOOD, 2011, 118 (21) : 1073 - 1073
[22] Prognostic value of combined WT1 and multiparameter flow cytometry assessment for measurable residual disease after induction in non-APL acute myeloid leukemia
Ding, Yangyang
Liu, Zelin
Wang, Huiping
Xiong, Shudao
Zhai, Zhimin
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2023, 83 (05): : 340 - 347
[23] Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia
Venditti, A
Maurillo, L
Buccisano, F
Tamburini, A
Del Poeta, G
Del Principe, MI
Panetta, P
Consalvo, MI
Mazzone, C
Tendas, A
Trawinska, M
Forte, V
Amadori, S
LEUKEMIA & LYMPHOMA, 2003, 44 (03) : 445 - 450
[24] Minimal Residual Disease Monitoring by Flow Cytometry in Pediatric Acute Myeloid Leukemia
Rubnitz, J.
ANNALS OF HEMATOLOGY, 2013, 92 : S55 - S55
[25] POST REMISSION MONITORING OF MINIMAL RESIDUAL DISEASE BY WT1 AND LEUKEMIA ASSOCIATED IMMUNOPHENOTYPE PREDICTS RELAPSE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS
Malagola, M.
Skert, C.
Borlenghi, E.
Morello, E.
Chiarini, M.
Giustini, V.
Comini, F.
Turra, A.
Cattina, F.
Cancelli, V.
Cerqui, E.
Pagani, C.
Passi, A.
Ribolla, R.
Schieppati, F.
Brenardi, S.
Perucca, S.
Di Palma, A.
Ruggeri, G.
Rossi, G.
Caimi, L.
Russo, D.
HAEMATOLOGICA, 2015, 100 : 382 - 382
[26] Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease
Tsuboi, A.
Oka, Y.
Kyo, T.
Katayama, Y.
Elisseeva, O. A.
Kawakami, M.
Nishida, S.
Morimoto, S.
Murao, A.
Nakajima, H.
Hosen, N.
Oji, Y.
Sugiyama, H.
LEUKEMIA, 2012, 26 (06) : 1410 - 1413
[27] Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia
Shah, Mithun Vinod
Jorgensen, Jeffrey L.
Saliba, Rima M.
Wang, Sa A.
Alousi, Amin M.
Andersson, Borje S.
Bashir, Qaiser
Ciurea, Stefan O.
Kebriaei, Partow
Marin, David
Patel, Keyur P.
Popat, Uday R.
Rezvani, Katy
Rondon, Gabriela
Shpall, Elizabeth J.
Champli, Richard E.
Oran, Betul
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (07) : 1514 - 1520
[28] Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis
Kern, W
Haferlach, T
MEDIZINISCHE KLINIK, 2005, 100 (01) : 54 - 59
[29] Minimal Residual Disease by Multiparametric Flow Cytometry Predicts Relapse Free Survival better than Over-Expression of WT1 and BAALC in Acute Myeloid Leukemia
Hasan, Syed Khizer
Patkar, Nikhil V.
Vishwakarma, Devanand
Rajamanickam, Deepen
Sahu, Arvind
Tembhare, Prashant
Kannan, Sadhna
Gujral, Sumeet
Bagal, Bhausaheb
Menon, Hari
Sengar, Manju
Amare, Pratibha Kadam
Subramanian, P. G.
Khattry, Navin
BLOOD, 2014, 124 (21)
[30] Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease
Qin, YaZhen
Zhu, HongHu
Jiang, Bin
Li, JinLan
Lu, XiJing
Li, LingDi
Ruan, GuoRui
Liu, YanRong
Chen, ShanShan
Huang, XiaoJun
LEUKEMIA RESEARCH, 2009, 33 (03) : 384 - 390

← 1 2 3 4 5 →